Akèy › Metiyè › Bioengineers and Biomedical Engineers › Austin, TX
Bioengineers and Biomedical Engineers nan Austin, TX: Salè H-1B
31 aplikasyon kondisyon travay pou okipasyon sa a ak yon sit travay nan Austin, TX. Salè baz medyàn ofri $101,500; mwatye mitan $82,072–$117,675.
Demann (LCA)31
Salè medyan ofri$101,500
Mwatye salè yo$82,072–$117,675
10yèm–90yèm pousantaj$71,599–$139,921
Pa nivo salè
| Nivo revni | Salè medyan |
|---|---|
| Nivo I (antre) | $73,143 |
| Nivo II (kalifye) | $105,680 |
| Nivo III (eksperyans) | $91,604 |
| Nivo IV (plen kompetans) | $140,000 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|---|---|
| The University of Texas at Austin | 12 | $80,080 |
| Paradromics, Inc. | 2 | $82,690 |
| Smith & Nephew, Inc. | 2 | $101,102 |
| Levels Health Inc. | 2 | $122,250 |
| Varian Medical Systems, Inc. | 2 | $142,011 |
| Blue Goji LLC | 2 | $105,000 |
| Neuralink Corp. | 2 | $100,517 |
| St. David's Medical Center | 1 | $83,928 |
| ClearCam Inc | 1 | $100,000 |
| Fresenius USA Marketing, Inc., a Fresenius Medical Care N.A. company | 1 | $103,000 |
| XBiotech USA Inc | 1 | $79,200 |
| Encore Medical LP | 1 | $150,000 |
| Abbott Laboratories | 1 | $140,000 |
| Cerevanta Inc. | 1 | $120,000 |
Tit travay
- Research Associate4
- Senior Research Fellow3
- Postdoctoral Fellow3
- Research and Development Engineer2
- Manager, Design Quality2
- Assistant Professor2
- Medical Device Test Engineer1
- Manager of Asset Management1
- Quality Assurance Engineer II - KBGFJG107966-51
- R&D Engineer1
- R&D Portfolio Manager1
- Data Analyst1
- Biomechanical Data Analyst1
- Clinical Research Associate1
- Augmented Reality Senior Software Engineer1
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).